NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 2.9 %

Shares of NeuroMetrix stock opened at $3.93 on Tuesday. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $5.96. The firm has a market capitalization of $7.90 million, a price-to-earnings ratio of -0.62 and a beta of 2.28. The firm’s 50 day simple moving average is $3.62 and its two-hundred day simple moving average is $3.84.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The company had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.